Deutsche Bank Starts Sarepta Therapeutic (SRPT) at Buy; Could Be Worth Up to $71/Sh
Tweet Send to a Friend
Deutsche Bank initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Buy and $45 price target calling RNA modulator, Eteplirsen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
